Surveillance after Focal Therapy - a Comprehensive Review

被引:3
作者
Marra, Giancarlo [1 ,2 ]
Marquis, Alessandro [1 ,2 ,3 ]
Suberville, Michel [4 ]
Woo, Henry [5 ,6 ]
Govorov, Alexander [7 ]
Hernandez-Porras, Andres [8 ]
Bhatti, Kamran [9 ]
Turkbey, Baris [10 ]
Katz, Aaron E. [11 ]
Polascik, Thomas J. [12 ,13 ]
机构
[1] Molinette Mauriziano Hosp, Dept Surg Sci, Div Urol, City Hlth & Sci, Turin, Italy
[2] Univ Turin, Turin, Italy
[3] Hofstra Northwell Univ, Smith Inst Urol, Zucker Sch Med, New York, NY 11549 USA
[4] Pole St Germain Ctr Hosp Brive, Dept Urol, Brive La Gaillarde, France
[5] Blacktown Mt Druitt Hosp, Dept Urol, Blacktown, NSW, Australia
[6] Chris OBrien Lifehouse, Dept Urooncol, Camperdown, NSW, Australia
[7] Botkin Hosp, Dept Urol, ROSUNIMED, Moscow, Russia
[8] Hosp Angeles, HoPe Robot Urol, Tijuana, Mexico
[9] Hamad Med Corp, Urol Dept, Alkhor, Qatar
[10] NCI, Mol Imaging Program, NIH, Bethesda, MD USA
[11] NYU Winthrop Hosp, Dept Urol, Garden City, NY USA
[12] Duke Med Ctr, Dept Urol, Durham, NC 27710 USA
[13] Duke Canc Inst, Duke Med Ctr, Durham, NC USA
关键词
INTENSITY FOCUSED ULTRASOUND; PROSTATE-CANCER RECOMMENDATIONS; DELPHI CONSENSUS; IRREVERSIBLE ELECTROPORATION; MRI; OUTCOMES; ABLATION; BIOPSY; TUMOR; HIFU;
D O I
10.1038/s41391-024-00905-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Backgroundto date, no standardized, evidence-based follow-up schemes exist for the monitoring of patients who underwent focal therapy (FT) and expert centers rely mainly on their own experience and/or institutional protocols. We aimed to perform a comprehensive review of the most advantageous follow-up strategies and their rationale after FT for prostate cancer (PCa).Methodsa narrative review of the literature was conducted to investigate different follow-up protocols of FT for PCa. Outcomes of interest were post-ablation oncological and functional outcomes and complications.ResultsOncological success after FT was generally defined as the biopsy-confirmed absence of clinically significant PCa in the treated zone. De novo PCa in the untreated area usually reflects an inaccurate patient selection and should be treated as primary PCa. During follow-up, oncological outcomes should be evaluated with periodic PSA, multiparametric MRI and prostate biopsy. The use of PSA derivatives and new biomarkers is still controversial and therefore not recommended. The first MRI after FT should be performed between 6-12 months to avoid ablation-related artifacts and diagnostic delay in case of FT failure. Other imaging modalities, such as PSMA PET/CT scan, are promising but still need to be validated in the post-FT setting. A 12-month "for-protocol" prostate biopsy, including targeted and systematic biopsy, was generally considered the preferred biopsy method to rule out tumor persistence/recurrence. Subsequent mpMRIs and biopsies should follow a risk-adapted approach depending on the clinical scenario. Functional outcomes should be periodically assessed using validated questionnaires within the first year, when typically recover to a new baseline. Complications, despite uncommon, should be strictly monitored mainly in the first month.ConclusionsFT follow-up is a multifaceted process involving clinical, radiological, and histological assessment. Studies evaluating the impact of different follow-up strategies and ideal timings are needed to produce standardized protocols following FT.
引用
收藏
页数:10
相关论文
共 84 条
[1]   Evaluation of Recurrent Disease after Radiation Therapy for Patients Considering Local Salvage Therapy: Past vs. Contemporary Management [J].
Adams, Eric S. ;
Deivasigamani, Sriram ;
Mottaghi, Mahdi ;
Huang, Jiaoti ;
Gupta, Rajan T. ;
Polascik, Thomas J. .
CANCERS, 2023, 15 (24)
[2]   Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study [J].
Ahmed, Hashim U. ;
Bosaily, Ahmed El-Shater ;
Brown, Louise C. ;
Gabe, Rhian ;
Kaplan, Richard ;
Parmar, Mahesh K. ;
Collaco-Moraes, Yolanda ;
Ward, Katie ;
Hindley, Richard G. ;
Freeman, Alex ;
Kirkham, Alex P. ;
Oldroyd, Robert ;
Parker, Chris ;
Emberton, Mark .
LANCET, 2017, 389 (10071) :815-822
[3]   Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model [J].
Alvim, Ricardo ;
Nagar, Karan ;
Das, Sudeep ;
Lebdai, Souhil ;
Wong, Nathan ;
Somma, Alexander ;
Hughes, Christopher ;
Thomas, Jasmine ;
Monette, Sebastien ;
Scherz, Avigdor ;
Kim, Kwanghee ;
Grimm, Jan ;
Coleman, Jonathan A. .
EUROPEAN UROLOGY FOCUS, 2021, 7 (02) :472-478
[4]  
Andolfi Ciro, 2022, Urology, V170, P154, DOI 10.1016/j.urology.2022.08.014
[5]   Padeliporfi n vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial [J].
Azzouzi, Abdel-Rahmene ;
Vincendeau, Sebastien ;
Barret, Eric ;
Cicco, Antony ;
Kleinclauss, Francois ;
van der Poel, Henk G. ;
Stief, Christian G. ;
Rassweiler, Jens ;
Salomon, Georg ;
Solsona, Eduardo ;
Alcaraz, Antonio ;
Tammela, Teuvo T. ;
Rosario, Derek J. ;
Gomez-Veiga, Francisco ;
Ahlgren, Goran ;
Benzaghou, Fawzi ;
Gaillac, Bertrand ;
Amzal, Billy ;
Debruyne, Frans M. J. ;
Fromont, Gaelle ;
Gratzke, Christian ;
Emberton, Mark .
LANCET ONCOLOGY, 2017, 18 (02) :181-191
[6]   The utility of intraoperative contrast-enhanced ultrasound in detecting residual disease after focal HIFU for localized prostate cancer [J].
Bacchetta, Frederic ;
Martins, Martina ;
Regusci, Stefano ;
Jichlinski, Patrice ;
Meuwly, Jean-Yves ;
Lucca, Ilaria ;
Valerio, Massimo .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (11) :846.e1-846.e7
[7]  
Bakavicius A, 2022, INT BRAZ J UROL, V48, P263, DOI [10.1590/S1677-5538.IBJU.2021.0091, 10.1590/s1677-5538.ibju.2021.0091]
[8]   Comprehensive Evaluation of Focal Therapy Complications in Prostate Cancer: A Standardized Methodology [J].
Bakavicius, Arnas ;
Sanchez-Salas, Rafael ;
Muttin, Fabio ;
Sivaraman, Arjun ;
Dell'Oglio, Paolo ;
Barret, Eric ;
Rozet, Francois ;
Mombet, Annick ;
Prapotnich, Dominique ;
Cathala, Nathalie ;
Cathelineau, Xavier .
JOURNAL OF ENDOUROLOGY, 2019, 33 (07) :509-515
[9]   Salvage irreversible electroporation for radio-recurrent prostate cancer - the prospective FIRE trial [J].
Blazevski, Alexandar ;
Geboers, Bart ;
Scheltema, Matthijs J. ;
Gondoputro, William ;
Doan, Paul ;
Katelaris, Athos ;
Agrawal, Shikha ;
Baretto, Daniela ;
Matthews, Jayne ;
Haynes, Anne-Maree ;
Delprado, Warick ;
Shnier, Ron ;
van den Bos, Willemien ;
Thompson, James E. ;
Lawrentschuk, Nathan ;
Stricker, Phillip D. .
BJU INTERNATIONAL, 2023, 131 :23-31
[10]   Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort [J].
Blazevski, Alexandar ;
Scheltema, Matthijs J. ;
Yuen, Brian ;
Masand, Natasha ;
Nguyen, Tuan, V ;
Delprado, Warick ;
Shnier, Ron ;
Haynes, Anne-Maree ;
Cusick, Thomas ;
Thompson, James ;
Stricker, Phillip .
EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (03) :283-290